We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

21 hedge funds and large institutions have $8.74M invested in vTv Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0.53% more ownership

Funds ownership: 21.9% → 22.43% (+0.53%)

0% more funds holding

Funds holding: 21 → 21 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

12% less capital invested

Capital invested by funds: $9.9M → $8.74M (-$1.16M)

Holders
21
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$276K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$29.6K
3
CCM
Connective Capital Management
California
+$6.14K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.2K
5
BlackRock
BlackRock
New York
+$2.25K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$21.9K
2
TRCT
Tower Research Capital (TRC)
New York
-$6.82K
3
Northern Trust
Northern Trust
Illinois
-$6.21K
4
SS
SBI Securities
Japan
-$147
5
JP Morgan Chase
JP Morgan Chase
New York
-$52
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$3.1M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.63M – – –
BBA
3
Baker Bros. Advisors
New York
$1.46M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$636K +$29.6K +1,617 +4%
Northern Trust
5
Northern Trust
Illinois
$229K -$6.21K -339 -2%
Millennium Management
6
Millennium Management
New York
$222K +$276K +15,042 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$190K +$4.2K +229 +2%
CCM
8
Connective Capital Management
California
$146K +$6.14K +335 +4%
BlackRock
9
BlackRock
New York
$72.4K +$2.25K +123 +3%
UBS Group
10
UBS Group
Switzerland
$42.7K -$21.9K -1,193 -30%
Morgan Stanley
11
Morgan Stanley
New York
$11.2K – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$2.55K +$330 +18 +12%
AWM
13
Activest Wealth Management
Florida
$750 – – –
CA
14
CoreCap Advisors
Michigan
$675 – – –
PA
15
Parallel Advisors
California
$570 – – –
SS
16
Sunbelt Securities
Texas
$207 – – –
Bank of America
17
Bank of America
North Carolina
$180 +$37 +2 +20%
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$135 – – –
SS
19
SBI Securities
Japan
$30 -$147 -8 -80%
Raymond James Financial
20
Raymond James Financial
Florida
$15 +$18 +1 New
SWP
21
Strategic Wealth Partners
Ohio
$15 +$18 +1 New
TRCT
22
Tower Research Capital (TRC)
New York
– -$6.82K -394 Closed
JP Morgan Chase
23
JP Morgan Chase
New York
– -$52 -3 Closed

VTVT Hedge Fund Activity: Q2 2025 in Review

21 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2025, worth a combined $8.74M — down 12% from $9.9M a quarter earlier.

Fund positioning in VTVT was balanced in Q2 2025: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $276K. The largest seller was UBS Group, cutting an estimated $21.9K.

  • 21 institutional investors held vTv Therapeutics (VTVT) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $8.74M of vTv Therapeutics stock for Q2 2025, down 12% quarter-over-quarter.
  • 3 funds opened new vTv Therapeutics positions in Q2 2025 and 3 closed out, a net change of 0 holders.
  • The largest vTv Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $276K added.
  • The largest vTv Therapeutics seller in Q2 2025 was UBS Group, an estimated $21.9K sold.

Based on aggregated 13F filings for Q2 2025.